Please login to the form below
Teva completes Cephalon purchase
Teva Pharmaceutical has acquired US-based biopharmaceutical company Cephalon for about $6.8bn following approval from the European Union
Teva Pharmaceutical has acquired US-based biopharmaceutical company Cephalon for about $6.8bn following approval from the European Union (EU).
The EU had demanded that Teva sell off its generic version of Cephalon's narcolepsy drug, Provigil (modafinil), to enable another company to own a competitor product.
Cephalon is now a wholly owned subsidiary of Teva, with Cephalon to receive $81.50 per share of common stock.
Teva said the combined company is to have a presence in over 60 countries. As individual companies, the combined revenue of Teva and Cephalon for the period July 2010 to June 2011 was around $20bn.
Shlomo Yanai, president and CEO of Teva, said the purchase was part of the Israel-based company's attempt to build its branded pharmaceuticals business through diversification and expansion of its product portfolio and pipeline.
Share
Related Hub content
Featured jobs
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
- Account Director or Senior Account Director
-
Salary TBC
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
-
Consultant
-
competitive salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Vice President
-
Competitive Salary Offered
Subscribe to our email news alerts
- Novartis links up with NHS for speedy access to cholesterol drug inclisiran
- NantKwest rockets on promising pancreatic cancer data
- FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC
- Genital herpes vaccine candidate heads for human studies
- Bayer bulks up in women’s health again with non-hormonal contraceptive deal
- Key success factor (KSF)
- How do companies prepare for reimbursement?
- Lucid Group adds more magic to the mix with four new hires
- Communiqué Awards 2020 is now open for entry
- Novo Nordisk gets MACE prevention claim for Ozempic in US
- NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
- FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- How do companies prepare for reimbursement?
- Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
- Integrating electronic health records into clinical trials
- How organisations are working to realise the research potential of EHRs...
- Keeping up the fight against HIV and using the lessons to tackle other threats
- Danny Buckland interviews Gilead’s Mike Elliott...
Quick links
Infographics
